NCT01352884 - Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-224 in Patients With Advanced Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

January 31, 2014

Conditions

Cancer

Interventions

DRUG

AMP-224

Escalating doses of AMP-224

DRUG

AMP-224

Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood

Trial Locations (4)

10065

Memorial Sloan Kettering Cancer Center, New York

28078

Carolina BioOncology Institute, Huntersville

37203

Sarah Cannon Research Institute, Nashville

48201

Karmanos Cancer Institute, Detroit